Bringing patients and providers together one tweet at a time

As an open forum for human interaction, social media have become the great equalizer of health information – providing a means for patients and health care providers to connect outside of the hospital or...

New treatment on horizon against ‘parasite’ mitochondria

A groundbreaking study has solved the old enigma in mitochondrial DNA disorders and advances the prospect of enhanced treatments for patients. It not only resolves a long-standing conundrum in the molecular pathology of mitochondrial disease,...

Personalised medicine: driving a need for greater diversity

Kate Shaw, CEO of Innovative Trials, investigates one of the biggest challenges facing clinical research today. Personalised medicines, particularly gene and cell therapies, offer new opportunities for treating serious conditions such as muscular dystrophy, cystic fibrosis...

TWO NEW FORMS OF THERAPY GIVE HOPE WHEN BLOOD CANCER RETURNS AND BOWEL CANCER...

Scientists trial new way to boost CAR T-cell therapy Cancer Research UK is collaborating with Aleta Biotherapeutics to trial a new therapy that reboots a treatment for some people whose blood cancer starts to come back. The new...

CRYONISS EARNS COVETED MHRA QUALITY MARK

Experts in biological sample, and medicinal product, storage and logistics management, CRYONISS offers a comprehensive storage service from ambient down to vapour phase liquid nitrogen. The Cheshire-based team has a wealth of experience in supporting...

UK ‘Octopus’ trial tackling multiple sclerosis is a world first

A ground breaking mega-trial for progressive multiple sclerosis will be launched in the UK later this year. Octopus, so called because of its multiple arms, is a revolutionary clinical trial that will transform the way...

Stay future-ready: Running parallel operations with a CDMO during clinical trials

Bringing a drug candidate through clinical trials is a challenging and high-risk process, since only 10% of candidates actually reach final approval. Both established pharma companies and small startups are often faced with this...

Pioneering technique paves way for fast and cheap fabrication of rapid medical diagnostic tools

Breakthrough promises to democratise microfluidics and lab-on-a-chip technology, benefiting resource-poor countries and settings. New technology developed by the University of Bristol has the potential to accelerate uptake and development of on-chip diagnostic techniques in parts...

Adult Vaccination

“Vaccination can provide cost-effective protection against a host of diseases throughout life, but remains an underused public-health strategy in adults for the promotion of healthy ageing. Without specific vaccination programmes for the adult population...

Lab-grown ‘mini-stomachs’ could shed light on children’s COVID symptoms

A ‘lab-grown model’ of the human stomach, that can be used to study how infections affect the gastrointestinal system, has been developed for the first time. A UCL-led team of international scientists have built on...

Shaping the science of oncology

Dr Fiona McLaughlin is the new Chief Scientific Officer of Avacta’s Therapeutics Division. She talks to Karen Southern about her mission to develop first and best-in-class cancer drugs. From the day that Dr McLaughlin –...

Making clinical trials right for older people

In this issue, we speak to Miles Witham, Professor of Trials for Older People at Newcastle University and consultant geriatrician, about why he’s bringing about a sea change in how clinical trials involving older...